Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids.

IF 3.4 3区医学 Q2 BIOCHEMISTRY & MOLECULAR BIOLOGY

Expert Opinion on Drug Metabolism & Toxicology Pub Date : 2022-07-01 Epub Date: 2022-08-23 DOI:10.1080/17425255.2022.2113381

Giulio Evangelisti, Fabio Barra, Umberto Perrone, Nadine Di Donato, Stefano Bogliolo, Marcello Ceccaroni, Simone Ferrero

{"title":"Comparing the pharmacokinetic and pharmacodynamic qualities of current and future therapies for uterine fibroids.","authors":"Giulio Evangelisti, Fabio Barra, Umberto Perrone, Nadine Di Donato, Stefano Bogliolo, Marcello Ceccaroni, Simone Ferrero","doi":"10.1080/17425255.2022.2113381","DOIUrl":null,"url":null,"abstract":"Introduction: Uterine fibroids are the most common benign gynecological tumors affecting women of reproductive ages. Although surgery is the definitive treatment choice, several medical approaches have been investigated to control their symptoms. The main issue of currently employed drugs for uterine fibroids is the long-term safety and tolerability profile. Today, new emerging options represent hopeful alternatives that could potentially overcome these limitations.Areas covered: This manuscript aims to give an updated overview of the pharmacodynamic and pharmacokinetic properties of current and new investigational medical drugs for the treatment of symptomatic uterine fibroids. The bibliographic research was conducted by searching alone or combined keywords on the following electronic databases: Medline, PubMed, Embase, Science Citation Index via Web of Science.Expert opinion: The most recent therapeutic strategies for uterine fibroids are represented by gonadotropin-releasing hormone antagonists (GnRH-ants; elagolix and relugolix) and selective progesterone receptor modulators (SPRM; ulipristal acetate). After early promising results, studies on innovative drugs, such as linzagolix (GnRH-ant) and vilaprisan (SPRM) are demanding. In the near future, a deeper knowledge of biological mechanisms at the basis of the genesis and growth of uterine fibroids could pave the way for the development of innovative targeted therapies.","PeriodicalId":12250,"journal":{"name":"Expert Opinion on Drug Metabolism & Toxicology","volume":" ","pages":"441-457"},"PeriodicalIF":3.4000,"publicationDate":"2022-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Drug Metabolism & Toxicology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17425255.2022.2113381","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2022/8/23 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Introduction: Uterine fibroids are the most common benign gynecological tumors affecting women of reproductive ages. Although surgery is the definitive treatment choice, several medical approaches have been investigated to control their symptoms. The main issue of currently employed drugs for uterine fibroids is the long-term safety and tolerability profile. Today, new emerging options represent hopeful alternatives that could potentially overcome these limitations.

Areas covered: This manuscript aims to give an updated overview of the pharmacodynamic and pharmacokinetic properties of current and new investigational medical drugs for the treatment of symptomatic uterine fibroids. The bibliographic research was conducted by searching alone or combined keywords on the following electronic databases: Medline, PubMed, Embase, Science Citation Index via Web of Science.

Expert opinion: The most recent therapeutic strategies for uterine fibroids are represented by gonadotropin-releasing hormone antagonists (GnRH-ants; elagolix and relugolix) and selective progesterone receptor modulators (SPRM; ulipristal acetate). After early promising results, studies on innovative drugs, such as linzagolix (GnRH-ant) and vilaprisan (SPRM) are demanding. In the near future, a deeper knowledge of biological mechanisms at the basis of the genesis and growth of uterine fibroids could pave the way for the development of innovative targeted therapies.

查看原文本刊更多论文

比较当前和未来治疗子宫肌瘤的药代动力学和药效学质量。

子宫肌瘤是影响育龄妇女最常见的妇科良性肿瘤。虽然手术是最终的治疗选择，但已经研究了几种医学方法来控制其症状。目前使用的子宫肌瘤药物的主要问题是长期的安全性和耐受性。今天，新出现的选择代表了有希望的替代方案，有可能克服这些限制。涵盖的领域:这篇论文的目的是对治疗症状性子宫肌瘤的现有和新的临床研究药物的药效学和药代动力学特性进行最新的概述。文献研究通过单独或组合关键词在以下电子数据库中进行检索:Medline、PubMed、Embase、Web of Science的Science Citation Index。专家意见:子宫肌瘤的最新治疗策略是促性腺激素释放激素拮抗剂(GnRH-ants;和选择性黄体酮受体调节剂(SPRM;ulipristal乙酸)。在早期有希望的结果之后，对创新药物，如linzagolix (GnRH-ant)和vilaprisan (SPRM)的研究要求很高。在不久的将来，对子宫肌瘤发生和生长的生物学机制的深入了解可以为创新靶向治疗的发展铺平道路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Opinion on Drug Metabolism & Toxicology 医学-生化与分子生物学

CiteScore

7.90

自引率

2.30%

发文量

审稿时长

4-8 weeks

期刊介绍： Expert Opinion on Drug Metabolism & Toxicology (ISSN 1742-5255 [print], 1744-7607 [electronic]) is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles on all aspects of ADME-Tox. Each article is structured to incorporate the author’s own expert opinion on the scope for future development. The Editors welcome: Reviews covering metabolic, pharmacokinetic and toxicological issues relating to specific drugs, drug-drug interactions, drug classes or their use in specific populations; issues relating to enzymes involved in the metabolism, disposition and excretion of drugs; techniques involved in the study of drug metabolism and toxicology; novel technologies for obtaining ADME-Tox data. Drug Evaluations reviewing the clinical, toxicological and pharmacokinetic data on a particular drug. The audience consists of scientists and managers in the pharmaceutical industry, pharmacologists, clinical toxicologists and related professionals.